San Diego-based Optimer Pharmaceuticals (NASDAQ: [[ticker:OPTR]]) said today it has raised $67.5 million through a stock offering. The company sold 6 million new shares at $11.25 apiece. The underwriters have an option to buy another 900,000 shares over the next 30 days, which would add more money to the deal. Jefferies & Co., Baird, Canaccord Genuity, JMP Securities, Needham & Co. and ThinkEquity managed the offering. Optimer plans to use the money to commercialize its first product, an antibiotic for ‘C.difficile’ infections, in the U.S. Earlier this week, Optimer said it struck a partnership with Astellas Pharma to market the drug outside the U.S.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
